Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $749.22 million. The enterprise value is $216.41 million.
Important Dates
The next estimated earnings date is Wednesday, February 25, 2026, after market close.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 87.02 million shares outstanding. The number of shares has increased by 4.45% in one year.
| Current Share Class | 87.02M |
| Shares Outstanding | 87.02M |
| Shares Change (YoY) | +4.45% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 74.14% |
| Float | 64.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.11 |
| Forward PS | 3.69 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | 8.98 |
| P/OCF Ratio | 8.50 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.60 |
Financial Position
The company has a current ratio of 5.12, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.12 |
| Quick Ratio | 4.83 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.23 |
| Interest Coverage | -152.85 |
Financial Efficiency
Return on equity (ROE) is -65.10% and return on invested capital (ROIC) is -42.68%.
| Return on Equity (ROE) | -65.10% |
| Return on Assets (ROA) | -26.57% |
| Return on Invested Capital (ROIC) | -42.68% |
| Return on Capital Employed (ROCE) | -45.41% |
| Revenue Per Employee | $541,818 |
| Profits Per Employee | -$1.13M |
| Employee Count | 192 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $2.24 million in taxes.
| Income Tax | 2.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.87% in the last 52 weeks. The beta is 0.25, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +18.87% |
| 50-Day Moving Average | 10.53 |
| 200-Day Moving Average | 8.03 |
| Relative Strength Index (RSI) | 34.87 |
| Average Volume (20 Days) | 1,537,047 |
Short Selling Information
The latest short interest is 11.31 million, so 13.00% of the outstanding shares have been sold short.
| Short Interest | 11.31M |
| Short Previous Month | 8.22M |
| Short % of Shares Out | 13.00% |
| Short % of Float | 17.62% |
| Short Ratio (days to cover) | 6.79 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $104.03 million and -$216.88 million in losses. Loss per share was -$2.48.
| Revenue | 104.03M |
| Gross Profit | -120.28M |
| Operating Income | -239.82M |
| Pretax Income | -214.64M |
| Net Income | -216.88M |
| EBITDA | -238.99M |
| EBIT | -239.82M |
| Loss Per Share | -$2.48 |
Full Income StatementBalance Sheet
The company has $549.67 million in cash and $19.47 million in debt, with a net cash position of $530.20 million or $6.09 per share.
| Cash & Cash Equivalents | 549.67M |
| Total Debt | 19.47M |
| Net Cash | 530.20M |
| Net Cash Per Share | $6.09 |
| Equity (Book Value) | 242.54M |
| Book Value Per Share | 2.79 |
| Working Capital | 499.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $87.80 million and capital expenditures -$4.69 million, giving a free cash flow of $83.11 million.
| Operating Cash Flow | 87.80M |
| Capital Expenditures | -4.69M |
| Free Cash Flow | 83.11M |
| FCF Per Share | $0.96 |
Full Cash Flow StatementMargins
Gross margin is -115.63%, with operating and profit margins of -230.53% and -208.48%.
| Gross Margin | -115.63% |
| Operating Margin | -230.53% |
| Pretax Margin | -206.33% |
| Profit Margin | -208.48% |
| EBITDA Margin | -229.73% |
| EBIT Margin | -230.53% |
| FCF Margin | 79.89% |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.45% |
| Shareholder Yield | -4.45% |
| Earnings Yield | -29.05% |
| FCF Yield | 11.13% |
Analyst Forecast
The average price target for Kura Oncology is $26.88, which is 212.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.88 |
| Price Target Difference | 212.20% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 68.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of -1.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.43 |
| Piotroski F-Score | 3 |
